Exelixis, Inc.
corporate_fare Company Profile
Exelixis, Inc. (NASDAQ:EXEL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for EXEL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for EXEL spans SCHEDULE 13D/A, 10-Q, 8-K, DEFA14A.
Recent high-impact activity:
- Farallon Sells ~2.6M Exelixis Shares Into Rally, Drops Below 5% Stake
- Exelixis 10-Q: Q3 Revenue $658.7M, EPS $0.85, $1.4B Cash, Handa Generic Approved
- Exelixis Q3 Revenue $658.7M, EPS $0.85; Tax Guidance Cut, Azurity Deal Signed
- Exelixis Q3 Revenue Jumps 10% to $658.7M, Tax Guidance Cut, New Zanzalintinib Readout Set for Q1 2027
- FDA Extends Zanzalintinib NDA Review by Three Months; New PDUFA Date March 3, 2027
Financial Snapshot
Short Interest & Short Volume
11.71 days to coverFINRA reported short interest of 25,593,708 shares in EXEL as of the October 30, 2026 settlement, a 6.3% decrease from the prior period — about 11.7 days to cover at its recent average daily volume. On November 20, 2026, 68.6% of EXEL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.